We are experiencing extremely high call volume related to COVID-19 vaccine interest. Please understand that our phone lines must be clear for people with urgent and acute medical care needs. Unfortunately, this means we are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this web site. Read more COVID-19 Vaccine Information
Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts
Enter the last name, specialty or keyword for your search below.
The Alyssa Parian Lab works to identify early markers of dysplasia. We also study inflammatory bowel disease-associated cancers, conduct IBD clinical trials and examine IBD extraintestinal manifestations.
The Brindusa Truta Lab studies inflammatory bowel diseases, specifically Crohn’s disease and ulcerative colitis. Recent studies defined factors associated with the development of Crohn's disease after ileal pouch anal anastomosis; determined the value of histology in identifying Lynch syndrome in early-onset of colorectal cancer patients; and compared the phenotype and genotype in adenomatous polyposis patients with and without a family history.
The Zhu lab is focused on characterizing the activities of large collection of proteins, building signaling networks for better understanding the mechanisms of biological processes, and identifying biomarkers in human diseases and cancers. More specifically, our group is interested in analyzing protein posttranslational modifications, and identifying important components involved in transcription networks and host-pathogen interactions on the proteomics level, and biomarkers in human IBD diseases.
Investigators in the IBD and Autoimmune Liver Diseases Laboratory conduct basic and translational research in inflammatory bowel disease (IBD) and autoimmune liver diseases. One area of focus is discovering and developing biomarkers for diagnosing and prognosticating IBD and other autoimmune liver diseases (AILDs). We also are exploring the molecular pathogenesis of—and developing novel therapies for—IBD. In addition, we are working to understand the molecular reason why many IBD patients fail to respond to mainstay drug therapies—and to develop diagnostic assays that can predict non-responders before starting them on those therapies. These biomarker studies have led to our application for four U.S. and international patents.
The Joanna Peloquin Lab focuses on inflammatory bowel disease (IBD). We're working on individualized care for IBD patients through functional genomic studies, specifically those related to diet, host and microbiota interactions.
Research in the Sharon Dudley Brown Lab focuses on gastroenterology and hepatology, inflammatory bowel disease and ulcerative colitis.
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
